United Therapeutics Insider Sale: Mahon’s 10(b)(5)(1) Plan Explained
Insider sale by United Therapeutics’ exec shows routine 10(b)(5)(1) liquidity, not a confidence hit—monitoring future filings for any shift.
5 minutes to read
United Therapeutics Corp
United Therapeutics Insider Sale: Benkowitz’s Routine Trade Signals Confidence and Market Strategy
Explore how United Therapeutics’ insider trade by President Benkowitz reveals a disciplined Rule 10b5‑1 strategy, a stable pipeline, and a forward‑looking stance on reimbursement and tech trends.
4 minutes to read